Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-11-16 DOI:10.1080/23723556.2021.2000318

Amanda K Riley, Alice H Berger

引用次数: 0

Abstract

In recent work, we performed CRISPR/Cas9 screening in RIT1 (Ras-like in all tissues)-mutant cancer cells. We found that RIT1-mutant cells are vulnerable to loss of mitotic regulators, and mutant RIT1 synergizes with YAP1 (yes-associated protein 1) in oncogenesis. These findings can be leveraged to identify targeted therapies for RIT1-mutant cancer.

查看原文本刊更多论文

全基因组CRISPR筛选揭示了RIT1-驱动的癌症的新治疗靶点。

在最近的工作中，我们在RIT1（所有组织中的Ras-like）突变癌症细胞中进行了CRISPR/Cas9筛选。我们发现RIT1突变细胞容易失去有丝分裂调节因子，并且突变RIT1在致癌过程中与YAP1（yes相关蛋白1）协同作用。这些发现可用于确定RIT1-毛特癌症的靶向治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.